89bio Welcomes New Chief Operating Officer Francis Sarena

In a significant move that underscores its commitment to advancing its position in the realm of clinical-stage biopharmaceuticals, San Francisco-based 89bio, Inc. ETNB has officially announced the appointment of Francis Sarena as its Chief Operating Officer. This strategic appointment comes at a time when the company is actively working on the development and eventual commercialization of novel therapies aimed at tackling liver and cardiometabolic diseases—a field that holds promise for addressing unmet medical needs.

Francis Sarena's Background and Role

Francis Sarena brings to 89bio a wealth of experience, which the company aims to leverage in order to streamline operations and propel its clinical programs forward. Sarena's track record of leadership and strategic planning in the biopharmaceutical sector is expected to play a pivotal role in advancing 89bio's pipeline of treatments, driving innovation, and potentially bringing new therapeutic options to patients globally.

89bio's Strategic Focus

ETNB's focus remains firmly on its clinical-stage pipeline, with an emphasis on creating treatments that can make a difference in the lives of those suffering from liver and cardiometabolic conditions. With its headquarters in the biotech hub of San Francisco, 89bio is strategically positioned to collaborate with other industry leaders and researchers to further its mission of delivering breakthrough therapies to the market.

appointment, biopharmaceuticals, leadership